NCT02216487View on ClinicalTrials.gov

Trial of FOLF(HA)Iri With Cetuximab in mCRC

PHASE2UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

November 30, 2016

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

HA-Irinotecan

HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.

Trial Locations (3)

1871

NOT_YET_RECRUITING

Liverpool Hospital, Sydney

2500

NOT_YET_RECRUITING

Southern Medical Day Care Centre, Wollongong

3021

RECRUITING

Western General Hospital, Melbourne

Sponsors

Collaborators (1)

Alchemia Oncology
All Listed Sponsors
collaborator

Alchemia Oncology

INDUSTRY

collaborator

Merck Serono International SA

INDUSTRY

lead

Western General Hospital, Australia

OTHER